immune system
• decrease in LPS-induced necroptosis
|
• increased inflammatory responses related to increased secretion of the proinflammatory cytokine interleukin (IL)-1beta in response to priming with lipopolysaccharide (LPS) followed bynigericin treatment
|
• reduced TNFalpha secretion in response to the TLR1/2 ligand PAM3CSK4
|
cellular
• decrease in LPS-induced necroptosis
|
• reduced MTT values of peritoneal exudate cells
|
hematopoietic system
• decrease in LPS-induced necroptosis
|